These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 28410294)
21. Image Gallery: Complete remission of aggressive desmoid-type fibromatosis after low-dose methotrexate for 2 weeks in a child with psoriasis. Simonsen S; Vera Casaño A; Gómez Moyano E; Sanz Trelles A; Bravo Bravo C; Martínez Pilar L Br J Dermatol; 2016 Oct; 175(4):e122. PubMed ID: 27650749 [No Abstract] [Full Text] [Related]
22. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of Metronomic Therapy as a Low-Cost, Sustainable, Standard-of-Care Option in Desmoid Fibromatosis: Real-World Data From a Tertiary Care Center in India. Bajpai J; Munot P; Kota K; Gupta G; Gala K; Gulia A; Rekhi B; Khanna N; Shetty N; Bhargava P; Srinivas S; Ostwal V; Patil V; Noronha V; Kulkarni S; Laskar S; Prabhash K; Chinnaswamy G; Gupta S; Banavali S JCO Glob Oncol; 2024 May; 10():e2300308. PubMed ID: 38723218 [TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. Skapek SX; Hawk BJ; Hoffer FA; Dahl GV; Granowetter L; Gebhardt MC; Ferguson WS; Grier HE J Clin Oncol; 1998 Sep; 16(9):3021-7. PubMed ID: 9738571 [TBL] [Abstract][Full Text] [Related]
25. The analysis of treatment of aggressive fibromatosis using oral methotrexate chemotherapy. Yoon GW; Kim JD; Chung SH Clin Orthop Surg; 2014 Dec; 6(4):439-42. PubMed ID: 25436069 [TBL] [Abstract][Full Text] [Related]
26. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Garbay D; Le Cesne A; Penel N; Chevreau C; Marec-Berard P; Blay JY; Debled M; Isambert N; Thyss A; Bompas E; Collard O; Salas S; Coindre JM; Bui B; Italiano A Ann Oncol; 2012 Jan; 23(1):182-186. PubMed ID: 21444357 [TBL] [Abstract][Full Text] [Related]
27. A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. Gennatas S; Chamberlain F; Smrke A; Stewart J; Hayes A; Roden L; Messiou C; Kowa JY; Estival A; Chauhan D; Thway K; Fisher C; van der Graaf WTA; Jones RL; Benson C Oncologist; 2020 Dec; 25(12):e2013-e2016. PubMed ID: 32918789 [TBL] [Abstract][Full Text] [Related]
28. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Gounder MM; Maddux L; Paty J; Atkinson TM Cancer; 2020 Feb; 126(3):531-539. PubMed ID: 31691276 [TBL] [Abstract][Full Text] [Related]
29. Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis-Letter. Zheng C; Min L; Tu C Clin Cancer Res; 2021 Apr; 27(7):2119. PubMed ID: 33795373 [No Abstract] [Full Text] [Related]
30. Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis-Response. Mir O; Honoré C; Chamseddine AN; Faron M; Haddag-Miliani L; Bayle A; Le Cesne A Clin Cancer Res; 2021 Apr; 27(7):2120. PubMed ID: 33795374 [No Abstract] [Full Text] [Related]
31. Is tumour location a prognostic factor for pharmacological treatment in patients with desmoid-type fibromatosis? a systematic review. Koike H; Hamada S; Sakai T; Shimizu K; Yoshida M; Nishida Y Jpn J Clin Oncol; 2020 Sep; 50(9):1032-1036. PubMed ID: 32533161 [TBL] [Abstract][Full Text] [Related]
32. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397 [TBL] [Abstract][Full Text] [Related]
34. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I Acta Oncol; 2011 Apr; 50(3):455-61. PubMed ID: 20799916 [TBL] [Abstract][Full Text] [Related]
35. Aggressive fibromatosis in children and adolescents: the Italian experience. Meazza C; Bisogno G; Gronchi A; Fiore M; Cecchetto G; Alaggio R; Milano GM; Casanova M; Carli M; Ferrari A Cancer; 2010 Jan; 116(1):233-40. PubMed ID: 19950127 [TBL] [Abstract][Full Text] [Related]
36. Medical treatment of mammary desmoid-type fibromatosis: which benefit? Scheer L; Lodi M; Molière S; Kurtz JE; Mathelin C World J Surg Oncol; 2017 Apr; 15(1):86. PubMed ID: 28420393 [TBL] [Abstract][Full Text] [Related]
37. Successful combined treatment for giant mesenteric desmoid tumor: case report and review of the literature. Federici S; Mordenti M; Domenichelli V; Pelusi G; Straziuso S; Pericoli R J Pediatr Surg; 2012 Jun; 47(6):e25-30. PubMed ID: 22703821 [TBL] [Abstract][Full Text] [Related]
38. Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. Eastley N; McCulloch T; Esler C; Hennig I; Fairbairn J; Gronchi A; Ashford R Eur J Surg Oncol; 2016 Jul; 42(7):1071-83. PubMed ID: 26965303 [TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic and genetic studies of desmoid-type fibromatosis]. Yang JL; Wang J; Zhou XY; Li XQ; Hou YY; Zhu XZ Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):145-50. PubMed ID: 16630502 [TBL] [Abstract][Full Text] [Related]
40. Pazopanib for progressive desmoid tumours: children, persistant effects, and cost. Nishida Y; Sakai T; Koike H; Ito K Lancet Oncol; 2019 Oct; 20(10):e555. PubMed ID: 31578997 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]